Valneva: The Lyme Royalty Transition Changes The Earnings Model

Impact · against what's priced in

Valneva is fundamentally pivoting toward a high-margin royalty model backed by promising Lyme vaccine data, which significantly improves its valuation profile and risk runway. Pfizer gains a validated asset for its portfolio, though the impact is smaller relative to its scale.

VALN+0.70: No priced-in read yet
In context: The transition from low-margin manufacturing to a high-margin royalty model, combined with 73% efficacy for the Lyme candidate and a three-year cash runway, materially changes the company's earnings trajectory.
Read from the article alone

Valneva: The Lyme Royalty Transition Changes The Earnings Model

biotech▲9%
PFE
VALN
cash runway
lyme disease
pharma partnership
restructuring
royalties
vaccines

Valneva: The Lyme Royalty Transition Changes The Earnings Model

What matters in this story

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

Valneva: The Lyme Royalty Transition Changes The Earnings Model

What matters in this story

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

How each ticker is affected

Connected tickers

Track these names every morning.

Recce Pharmaceuticals signs Arrotex deal for RECCE 327 in Australia and New Zealand

BBNX DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

UNCY FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY

Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health Transcript

Valneva: The Lyme Royalty Transition Changes The Earnings Model

What matters in this story

Next reads from the same story arc

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

Valneva: The Lyme Royalty Transition Changes The Earnings Model

What matters in this story

Next reads from the same story arc

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

How each ticker is affected

Connected tickers

Track these names every morning.

Recce Pharmaceuticals signs Arrotex deal for RECCE 327 in Australia and New Zealand

BBNX DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

UNCY FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY

Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health Transcript